SKIN The Journal of Cutaneous Medicine
Verified
Journal
SKIN is a bi-monthly, peer-reviewed, online medical journal dedicated to providing an enhanced route to disseminate new dermatologic knowledge on all aspects of cutaneous disease.
https://jofskin.org/index.php/skin/about/submissions Source
Actions
Media Outlet details
| Scope | International, Trade/B2B |
|---|---|
| Language | English |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
| Frequency | Bimonthly |
| Accepts contributed content | Yes |
Recent Articles
Search ArticlesAvoiding the Danger of Rising Resistance in Cutibacterium acnes: Criticality of Benzoyl Peroxide and Antibiotic Fixed Combinations
Main Article Content Mahmoud Ghannoum Ahmed Gamal Ahmed Kadry James Del Rosso Christopher Bunick Linda Stein Gold Leon Kircik Julie Harper Keywords acne, combination treatment, C. acnes, susceptibility, resistance, clindamycin, benzoyl peroxide Abstract References 1. Jesitus J. Dermatol Times. https://www.dermatologytimes.com/view/dermatologists-contribute-overuse-antibiotics. 2. Crawford WW, et al. J Invest Dermatol. 1979;72(4):187-90. 3. Thiboutot D, Gollnick H, Bettoli V, et al. J Am Acad Dermatol.
A Twelve Week Study Evaluating the Efficacy of a Novel Standardized Nutraceutical to Improve Acne and Skin Health
INTRODUCTION Although acne is generally viewed as the result of a localized immune response at the pilosebaceous unit, it is a condition with multifactorial etiology. While conventional treatments have focused primarily on the four major pathogenic factors, nutraceuticals offer an alternative or complementary approach to address more systemic, intertwined mechanisms involved in acne pathogenesis.
Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Analysis of Mental Health and Associated Disorders
Main Article Content Keywords bimekizumab, psoriasis, safety, mental health, suicide, suicidality, plaque psoriasis, depression, clinical trial Abstract References 1. Kurd SK et al. Arch Dermatol 2010;146:891–5; 2. Kroenke K et al. J Gen Intern Med 2001;16:606–13; 3. Strober B et al. Br J Dermatol 2023;188:749–59, NCT03598790; 4. Reich K et al. Lancet 2021;397:487–98, NCT03370133; 5. Gordon KB et al. Lancet 2021;397:475–86, NCT03410992; 6. Warren RB et al. N Engl J Med 2021;385:130–41, NCT03412747; 7.
Treatment or Psoriasis with Calcipotriene and Betamethasone Dipropionate (CAL/BDP) Cream Showed Significantly Higher Proportion of Patients with an Absolute mPASI≤2 Compared to CAL/BDP Gel/Topical Suspension in a Post-Hoc Aanalysis of Two Phase 3 Studies
1. Praestagaard M, Steele F, Crutchley N. Polyaphron Dispersion Technology, A novel topical formulation and delivery system combining drug penetration, local tolerability and convenience of application. Dermatol Ther (Heidelb.). 2002;12(10):2217-2231. 2. Mahil SK, Wilson N, Dand N, Reynolds NJ, Griffiths CEM, Emsley R, et al.
Clinical Burden and Impairment in Moderate-to-Severe Atopic Dermatitis
Main Article Content Keywords atopic dermatitis, work productivity and activity impairment, disease burden, comorbidity References Andersen, L., M.E. Nyeland, and F. Nyberg, Increasing severity of atopic dermatitis is associated with a negative impact on work productivity among adults with atopic dermatitis in France, Germany, the U.K. and the U.S.A. Br J Dermatol, 2020. 182(4): p. 1007-1016.
Cellular Deconvolution Reveals Unique Findings in Several Cell Type Fractions Within the Basal Cell Carcinoma Tumor Microenvironment
1. Leavitt, E., Lask, G., & Martin, S. (2019). Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma. Current treatment options in oncology, 20(11), 84. https://doi.org/10.1007/s11864-019-0683-9 2. Wan, J., Dai, H., Zhang, X., Liu, S., Lin, Y., Somani, A. K., Xie, J., & Han, J. (2019). Distinct transcriptomic landscapes of cutaneous basal cell carcinomas and squamous cell carcinomas. Genes & diseases, 8(2), 181–192. https://doi.org/10.1016/j.gendis.2019.10.004 3.
Patient Preferences in Moderate-to-Severe Atopic Dermatitis (AD): A Discrete Choice Experiment (DCE)
Main Article Content Keywords atopic dermatitis, patient preferences, drug attributes, discrete choice experiment References 1. Silverberg, J.I., et al., Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Annals of Allergy, Asthma & Immunology, 2018. 121(3): p. 340-347. 2. Ervin, C., et al., Patient and caregiver preferences on treatment attributes for atopic dermatitis. Journal of Dermatological Treatment, 2022. 33(4): p. 2225-2233 3.
Lebrikizumab Provides Progressive Improvements in Skin Clearance and Itch Relief Over One Year in Patients with Atopic Dermatitis
Article Details How to Cite Armstrong, A. ., Ghoreschi, K. ., Rosmarin, D. ., Schlesinger, T. ., Irvine, A. ., Bewley, A. ., Casillas, M. ., Gallo, G. ., Ding, Y. ., Xu, C. ., Pau-Charles, I. ., & Simpson, E. . (2023). Lebrikizumab Provides Progressive Improvements in Skin Clearance and Itch Relief Over One Year in Patients with Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine, 7(6), s278.
Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Treated With Baricitinib: An Update Through Week 152 From BRAVE-AA2
This work is licensed under a Creative Commons Attribution 4.0 International License. All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose.
Baricitinib Treatment Increases Eyebrow and Eyelash Regrowth Up to 52 Weeks
Article Details How to Cite Mostaghimi, A. ., Piliang, M. ., Lynde, C. ., Szepietowski, J. C. ., Jedynak, J. P. ., Somani, N. ., Lu, N. ., Yu, G. ., Chiasserini, C. ., & Hordinsky, M. . (2023). Baricitinib Treatment Increases Eyebrow and Eyelash Regrowth Up to 52 Weeks. SKIN The Journal of Cutaneous Medicine, 7(6), s297. https://doi.org/10.25251/skin.7.supp.297 Section Alopecia This work is licensed under a Creative Commons Attribution 4.0 International License. All authors retain copyright in their articles.